Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The U.S. House of Representatives has split with the Senate over requiring pharmaceutical companies to disclose the list price of their prescription medications in television advertisements.
Shares of Cambridge, Mass.-based Mersana Therapeutics are up more than 7 percent in premarket trading after the company announced that it will be able to continue with its Phase I trial studying the antibody drug conjugate XMT-1522 as a potential treatment for some breast cancer patients.
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial on Sunday that showed its triple combination therapy PT010 outperformed its dual-therapy rivals eight of nine times.
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb gave a talk at The Pew Charitable Trusts on Friday, September 14, outlining the agency’s new approach to dealing with antimicrobial resistance (AMR).
The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ajovy (fremanezumab) to prevent migraine on Friday, September 16.
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA’s decision to delay a ruling for its Parkinson’s disease treatment.
Atlantic Healthcare plc has secured acceptance of Camligo™ as the name for the Company’s first candidate product.
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
Purdue Pharma, best known for being the manufacturer of opioid drug OxyContin, is offering free doses of a treatment for opioid abuse as part of negotiations in more than 1,000 lawsuits.
WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of fruquintinib capsules (Elunate®) for metastatic colorectal cancer from the National Medical Products Administration of China